<?xml version="1.0" encoding="UTF-8"?>
<p>The ProCID study is a randomised, double‐blind, multi‐centre, phase III trial that has been designed to compare 3 different IVIg maintenance doses for the treatment of patients with CIDP: 0.5, 1.0, and 2.0 g/kg once every 3 weeks for 24 weeks. The use of 3 maintenance dose groups in the dose‐evaluation phase will allow for confirmation of the clinical efficacy of IVIg observed in previous clinical trials.
 <xref rid="jns12267-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="jns12267-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="jns12267-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="jns12267-bib-0006" ref-type="ref">6</xref>, 
 <xref rid="jns12267-bib-0007" ref-type="ref">7</xref>, 
 <xref rid="jns12267-bib-0008" ref-type="ref">8</xref>, 
 <xref rid="jns12267-bib-0009" ref-type="ref">9</xref>, 
 <xref rid="jns12267-bib-0010" ref-type="ref">10</xref>, 
 <xref rid="jns12267-bib-0011" ref-type="ref">11</xref>, 
 <xref rid="jns12267-bib-0012" ref-type="ref">12</xref>
</p>
